Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 13/20 | 0.59 |
| ▸ | WNT3A | P56704 | 13/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31525070 | 1.00 | CTNNB1 (0.59) | CTNNB1WNT3ALMNAGAAHDAC3 | |
| SCHEMBL30089582 | 0.86 | CTNNB1 (0.75) | CTNNB1WNT3ALMNAGAA | |
| SCHEMBL5851305 | 0.85 | CTNNB1 (0.60) | CTNNB1WNT3ALMNAGAAHDAC3 | |
| SCHEMBL5543911 | 0.83 | CTNNB1 (0.59) | CTNNB1WNT3ALMNAGAAHDAC3 | |
| SCHEMBL3732487 | 0.83 | CTNNB1 (0.59) | CTNNB1WNT3ALMNAGAA | |
| SCHEMBL8232789 | 0.82 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAAPTGS1 | |
| SCHEMBL5660835 | 0.82 | CTNNB1 (0.58) | CTNNB1WNT3ALMNAGAAHDAC3 | |
| SCHEMBL27629360 | 0.82 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAA | |
| SCHEMBL5540580 | 0.82 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAAHDAC3 | |
| Ammonia Solution, Strong SCHEMBL28847475 | 0.81 | CTNNB1 (0.55) | CTNNB1WNT3ALMNAGAAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-112437772-B | Bcl-2 inhibitors | 百济神州有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-112437772-A | Bcl-2 inhibitors | 百济神州有限公司 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | CTNNB1 2247/4885WNT3A 3061/4885LMNA 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.